- Home
- ALLR vs ATHA Comparison
ALLR vs ATHA Comparison
Compare ALLR & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- ATHA
- Stock Information
- Founded
- ALLR 2004
- ATHA 2011
- Country
- ALLR United States
- ATHA United States
- Employees
- ALLR N/A
- ATHA N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- ALLR Health Care
- ATHA Health Care
- Exchange
- ALLR Nasdaq
- ATHA Nasdaq
- Market Cap
- ALLR 15.8M
- ATHA 14.8M
- IPO Year
- ALLR N/A
- ATHA 2020
- Fundamental
- Price
- ALLR $0.94
- ATHA $0.40
- Analyst Decision
- ALLR Strong Buy
- ATHA Hold
- Analyst Count
- ALLR 1
- ATHA 3
- Target Price
- ALLR $9.00
- ATHA $0.50
- AVG Volume (30 Days)
- ALLR 367.8K
- ATHA 133.3K
- Earning Date
- ALLR 08-15-2025
- ATHA 08-07-2025
- Dividend Yield
- ALLR N/A
- ATHA N/A
- EPS Growth
- ALLR N/A
- ATHA N/A
- EPS
- ALLR N/A
- ATHA N/A
- Revenue
- ALLR N/A
- ATHA N/A
- Revenue This Year
- ALLR N/A
- ATHA N/A
- Revenue Next Year
- ALLR N/A
- ATHA N/A
- P/E Ratio
- ALLR N/A
- ATHA N/A
- Revenue Growth
- ALLR N/A
- ATHA N/A
- 52 Week Low
- ALLR $0.61
- ATHA $0.22
- 52 Week High
- ALLR $6.00
- ATHA $3.51
- Technical
- Relative Strength Index (RSI)
- ALLR 47.03
- ATHA 53.29
- Support Level
- ALLR $0.85
- ATHA $0.38
- Resistance Level
- ALLR $1.01
- ATHA $0.41
- Average True Range (ATR)
- ALLR 0.05
- ATHA 0.02
- MACD
- ALLR -0.01
- ATHA -0.00
- Stochastic Oscillator
- ALLR 47.55
- ATHA 71.70
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.